South Korea drug pricing and reimbursement: key facts
Channels and distribution
Where do generic drug makers win sales in Korea, clinics or hospitals?
Clinics favour generic-led firms with large, well-trained rep forces and low prices, while established firms target general and university hospitals, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).
Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
Is national reimbursement listing enough to get a new drug onto hospital formularies in Korea?
No: each hospital's drug committee adds a product to its formulary separately, and price influences inclusion, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).
Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
Which hospitals tend to become a new drug's first formulary wins in Korea?
Hospitals hosting a maker's clinical trial tend to become its first formulary wins, and reps later use the hospital's name, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).
Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
Pricing
Does a price request get more scrutiny in Korea's drug price review?
Officials look hard at expensive filings, while a filing asking for a reasonable price usually passes without a second review, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).
Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
Regulation
Can a foreign importer expect the modified-drug price premium in Korea, and for how long?
Importers should not expect the premium local producers keep; the term is 1 year, extended 2 years at a time (Dailypharm, 6 May 2026), as cited in KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).
Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
Market entry
What does a late generic entrant face in Korea once many copies are listed?
Being a late entrant at the lowest list price, without a strong rep force, is a listing rather than a business, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).
Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
What should a foreign drug maker without hospital coverage do before launching in Korea?
Firms without hospital coverage or a rep force should find a partner before launch, not after, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).
Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
Risks
What do originators do when local copies arrive after patent expiry in Korea?
Many local copies arrive within months; originators defend with outcome data, new strengths or indications and selective price cuts, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).
Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
How the trade works
How has drug promotion to doctors in Korea changed after official warnings?
After official warnings over illegal support to prescribers, firms cut sponsorship and leaned on clinical data in promotion, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).
Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
How is a generic drug's reimbursement price checked in Korea?
Reviewers check a generic's price against ministry rules using the company's documents, with little capacity to re-check each number, per KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul).
Source: KIRA field research (modelled interview), 2026 · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
Who decides
Practitioner views from KIRA Experts transcripts: modelled interviews built on KIRA's field interviews. How we work: Methodology.
Who specifies
- Doctors' acceptance of a modified copy of a leading molecule depends on local clinical data and on the hospital formulary decision. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul)
- Companies hire managers with past regulator experience because they are seen to help approval, listing and promotion. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul)
Who buys and pays
- When a low-price product stops making money, the company quietly stops producing rather than arguing about the price. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul)
- The company carries the consequence of its own filing: a missing drug-substance certificate is not debated but leads to a lower price. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul)
Who carries the risk
No field statement yet
How the trade works
Practitioner views from KIRA Experts transcripts: modelled interviews built on KIRA's field interviews. How we work: Methodology.
- Pressure on the insurance fund steadily pushes pricing officials to favour cheaper drugs and to re-evaluate off-patent originator prices. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
- National listing is not enough: each hospital's drug committee adds the product to its formulary separately, and price influences inclusion. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
- When a low-price product stops making money, the company quietly stops producing rather than arguing about the price. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
- Publicly announced launch sales targets are often inflated as a form of advertising, and the firm's own sales staff see them as unrealistic. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
- The company carries the consequence of its own filing: a missing drug-substance certificate is not debated but leads to a lower price. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
- Firms new to a therapy area use an existing product as a door-opener with the same doctors, then promote the new product alongside it in package deals. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
- Reviewers check generic and modified-drug price applications against the ministry's pricing principles, using the documents companies submit, and have limited capacity to verify company data. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
- Doctors' acceptance of a modified copy of a leading molecule depends on local clinical data and on the hospital formulary decision. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
- Companies hire managers with past regulator experience because they are seen to help approval, listing and promotion. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
- Generic-led firms win in clinics with large, well-trained rep forces and low prices, while established firms target general and university hospitals and lean on corporate image. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
- After official warnings over illegal support to prescribers, firms cut sponsorship and lean more on clinical data in promotion. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
- Hospitals that host a company's clinical trial tend to become its first formulary wins and first sales base, and reps use the trial hospital's name after launch. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
- Filings that ask for a reasonable price usually go through without a second review, while officials look hard at expensive ones. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original
- When a blockbuster loses its patent, many local copies arrive within months and competition turns to price; originators defend with outcome data, new strengths or indications and selective price cuts. former reimbursement pricing official now advising drug makers on listings · KIRA field research (interviews with health insurance pricing officials, local drug makers' product and marketing managers, industry analysts and hospital cardiologists in Seoul) · How Korea now prices a generic or a modified drug for reimbursement, after the cut to 45% of the original